Financial Innovations for Early-Stage Drug Development
Monday, April 30, 2012 / 11:00 am - 12:15 pm
, Deputy Executive Director, FasterCures / The Center for Accelerating Medical Solutions
, President and CEO, Kite Pharma; Venture Partner, Orbimed Partners
, Harris & Harris Group Professor, MIT Sloan School of Management
, Founder, InnoThink Center for Research in Biomedical Innovation
Translational research - the point at which general scientific knowledge starts to be applied to addressing a specific disease or condition - is the first step on the path to developing a new drug. But traditional investors in translational research (large- and medium-cap biopharmaceutical companies and life science-focused venture capital funds) are becoming increasingly risk averse in the face of escalating challenges in the drug development process. FasterCures recently hosted a Financial Innovations Lab to examine business models and financial instruments that can improve the risk/return ratio for early-stage investors. In this session you'll hear from experts who have designed and implemented new models like leveraged funds, research-based obligations and collaborative funding. If we can find a way to close the funding gap for translational research, we can get one step closer to urgently needed treatments.